New PDUFA action date announced by the US FDA for Injectafer® New Drug Application
April 08, 2013 01:16 ET
|
Vifor Pharma Ltd.
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;} Vifor Pharma today announced that its US partner,...
Demande d'autorisation de PA21 déposée en Suisse
March 12, 2013 02:15 ET
|
Vifor Pharma Ltd.
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;} Une demande d'autorisation de PA21 en Suisse a été...
Zulassungsantrag für PA21 in der Schweiz eingereicht
March 12, 2013 02:15 ET
|
Vifor Pharma Ltd.
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;} Für PA21 wurde beim Schweizerischen Heilmittelinstitut...
PA21 authorisation application submitted in Switzerland
March 12, 2013 02:15 ET
|
Vifor Pharma Ltd.
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;} An application for the authorisation of PA21 in...
PA21 dossier submitted for approval to US FDA
February 11, 2013 01:05 ET
|
Vifor Pharma Ltd.
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;} The New Drug Application (NDA) for PA21 has been...
Observational study suggests a role for Ferinject® (ferric carboxymaltose) in optimizing the care of anaemic and iron deficient patients with cancer
January 31, 2013 01:15 ET
|
Vifor Pharma Ltd.
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;} On the eve of World Cancer Day, Vifor Pharma notes...
Vifor Pharma and China Medical System Holdings Limited sign distribution agreement for Maltofer® and Uro-Vaxom® in China
January 17, 2013 02:00 ET
|
Vifor Pharma Ltd.
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;} Vifor Pharma, a company of the Galenica Group, today...
PA21 Pivotal phase III data presented at American Society of Nephrology (ASN) Kidney Week demonstrate successful control of hyperphosphatemia with lower pill burden for patients
November 05, 2012 04:00 ET
|
Vifor Pharma Ltd.
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;} Data from a pivotal phase III clinical study of new...
Venofer® (Iron Sucrose Injection, USP) receives US FDA approval for Paediatric Indication
September 26, 2012 07:00 ET
|
Vifor Pharma Ltd.
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;} Vifor Pharma, a company of the Galenica group, is...
New Guidelines Issued by a Number of Global Medical Committees Prioritise Management of Iron Deficiency to Improve Patient Outcomes
September 17, 2012 04:00 ET
|
Vifor Pharma Ltd.
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;} - The new Kidney Disease Guideline: Improving Global...